In recent years, there have been major advances in the imaging of myeloma with whole body MRI incorporating diffusion-weighted imaging, emerging as the most sensitive modality. Imaging is now a key component in the work-up of patients with a suspected diagnosis of myeloma. The International Myeloma Working Group now specifies that more than one focal lesion on MRI or lytic lesion on whole body low-dose CT or fludeoxyglucose (FDG) PET/CT fulfil the criteria for bone damage requiring therapy. The recent National Institute for Health and Care Excellence myeloma guidelines recommend imaging in all patients with suspected myeloma. In addition, there is emerging data supporting the use of functional imaging techniques (WB-DW MRI and FDG PET/CT) to predict outcome and evaluate response to therapy. This review summarises the imaging modalities used in myeloma, the latest guidelines relevant to imaging and future directions. 2 of 13 birpublications.org/bjr Br J Radiol;92:20180768 BJR Barwick et al 3 of 13 birpublications.org/bjr Br J Radiol;92:20180768 BJR Review article: Advanced imaging in myeloma

A retrospective case note review of postoperative infections within 30 days of colorectal surgery was completed. Surgical site infections (SSIs) were identified in 22% of patients (84/378), with other infections, e.g. urinary tract infections, identified in 18.3% of patients. SSIs, urinary and respiratory tract infections were all associated with increased durations of hospital admission compared with non-infected patients. Consideration should be given to postoperative surveillance for all infections, using antibiotic consumption as an objective outcome measure. Nine percent of patients developed an organ space SSI. Organ space SSIs were associated with the longest additional duration of hospital admission (15.5 days) and were the only infection associated with an increase in mortality at 1 year; 37% (13/35) mortality with an organ space SSI vs 4% (8/225) without an infection (odds ratio = 16, 95% confidence interval = 6, 43). Further research to prevent and treat organ space SSIs should be prioritized.

MR-guided focussed ultrasound surgery (MRgFUS) allows for precise non-invasive thermal ablation of target tissues for a wide range of clinical applications. It is an innovative and rapidly expanding technology, which has already established itself as an effective and safe incisionless alternative in the treatment of various soft tissue tumours, with many more research studies underway to extend its therapeutic envelope. The non-invasiveness of the procedure makes FUS particularly attractive in functional neurosurgery, where existing treatment options are not suitable for all patients. Several clinical trials have demonstrated the feasibility and favourable safety profile of MR-guided focused ultrasound surgery in essential tremor, Parkinson's disease and other neurological conditions. This article reviews the existing evidence base for the neurological applications of FUS and the evidence for its emerging roles in the treatment of a range of brain disorders.

Apomorphine SL is more effective than placebos in treating ED and is generally well tolerated in the sublingual formulation, causing tolerable side effects. Newer nasal-spray formulations provide faster efficacy. Its efficacy in patients with multiple co-morbidities is more limited. However, it is not as effective as PDE5-I in the treatment of ED. Its most significant strength is its safety profile. It may have a niche in the treatment ED in patients who have failed treatment with, or are intolerant to other well-established pharmacological treatment for ED (e.g., PDE5-Is). Apomorphine is not a first-line treatment option for patients with ED, especially as it is no more widely available in the western world.